Abstract
In a recent article in Molecular Therapy – Methods and Clinical Development, Galanis and co-authors presented pre-clinical safety data for a cancer immunotherapy derived from a measles vaccine strain, engineered to encode a bacterial immunomodulator.1 These data supported a successful investigational new drug (IND) application for a phase I clinical trial for patients suffering from metastatic breast cancer that is now ongoing. Despite limitations of the mouse model, the pre-clinical data from the present study and prior work are encouraging.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Molecular Therapy - Methods & Clinical Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
